Mark Wefers Bettink

Interim analysis; Feasibility study of measurement of mitochondrial function in patients with sepsis 7 137 The mitoVO 2 for the first and second measurement in the control group were -6.4 [-4.5 ; -6.7] mmHg s -1 and -5.1 [-4.0 ; -6.0] mmHg s -1 . In the sepsis group an mitoVO 2 was measured of -7.3 [-3.5 ; -8.5] mmHg s -1 and -5.4 [-3.0 ; -7.9] mmHg s -1 for the first and second measurement respectively. M1 M2 M1 M2 0 20 40 60 80 100 MitoPO 2 (mmHg) MitoPO 2 M1 M2 M1 M2 -15 -10 -5 0 MitoVO 2 (mmhg*s -1 ) MitoVO 2 Sepsis Control A B Figure 2 Results of COMET monitor measurements. Median and individual values. M1 is the measurement at ≤ 24 hours after admission to the ICU andM2 5 – 7 days after the first measurement (A) Median baseline mitochondrial oxygen tension (mitoPO 2 ) of the first and second measurement of the control group [n = 5] and [n = 3] and sepsis group [n = 7] and [n = 2] in (B) Median mitochondrial oxygen consumption rate (mitoVO 2 ) of the first and second measurement of the control group [n = 6] and [n = 5] and of the sepsis group [n = 7] and [n = 2] in mmHg. Ex vivo platelet respiration The respiration measurements on platelets were performed a median of 20.4 hours after ICU admission. The final platelet count in the O2k chamber was a median of 56 [23.5 : 110] * 10 6 platelets / mL. Following an average of 7 FCCP additions maximal respiratory rate was reached. We found an unstimulated oxygen consumption of 5.2 [1.4 ; 8.0] pmol/ (s* 10 6 platelets) and 6.0 [4.2 ; 15.9] pmol/(s* 10 6 platelets) for the control and sepsis measurements respectively. An state 4o of 0.1 [-3.8 ; 2.0] pmol/(s* 10 6 platelets) and 2.9 [1.6 ; 14.0] pmol/(s* 10 6 platelets) and maximal flux of 13.7 [11.7 ; 16.4] pmol/(s* 10 6 platelets) and 28.7 [3.9 ; 53.0] pmol/(s* 10 6 platelets) for control and sepsis respectively as shown in figure 3A for measurement at admittance and figure 3B for measurement at 5-7 days after the first measurement.